Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Emerging treatment options for refractory immune thrombocytopenia

Hanny Al-Samkari • 9 Dec 2023
ASH 2023
Immune Thrombocytopenia Non-Malignant BTK inhibitors Efgartigimod Rilzabrutinib Sovleplenib
LUNA3

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses emerging treatment options for refractory immune thrombocytopenia (ITP). For those patients who do not respond to all current treatment options, there are several new therapies in development. The Fc receptor inhibitor efgartigimod has been efficacious in IV formulations, and the BTK inhibitor rilzabrutinib is expected to produce positive results following the completion of the Phase III LUNA3 trial (NCT04562766). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hanny Al-Samkari

1:25
Improving the sensitivity of platelet autoantibody testing for ITP diagnosis
Hanny Al-Samkari • 9 Dec 2023
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
1:46
Avatrombopag in patients with early versus chronic immune thrombocytopenia
Hanny Al-Samkari • 9 Dec 2023
2:55
The role of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia
Hanny Al-Samkari • 25 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals